Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.59 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472608 | 1.00 | PTGS1 (0.65) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4482250 | 0.88 | PTGS1 (0.70) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30436399 | 0.85 | PTGS2 (0.74) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9555892 | 0.85 | PTGS2 (0.74) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5751142 | 0.85 | MMP8 (0.50) | MAPTSMN1; SMN2ALDH1A1LMNACYP3A4 | |
| Dimethylamine SCHEMBL3834248 | 0.84 | PTGS2 (0.72) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4470465 | 0.84 | PTGS1 (0.69) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4470755 | 0.84 | PTGS1 (0.69) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4470462 | 0.84 | PTGS1 (0.69) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL31113389 | 0.82 | PTGS1 (0.71) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | claimed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | claimed |
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-1581474-B1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE SPA (IT) | 2008-08-27 | — | — | EP | disclosed |
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE PHA.R.MA S.P.A. (IT) | 2006-11-02 | — | — | US | disclosed |
| EP-1581474-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | Dompé S.P.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
| US-5258396-A | Thiazole derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-11-02 | — | — | US | disclosed |
| EP-0511021-A1 | Novel thiazole derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247297-A1 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885MAPT 1794/4885 |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | PTGS1 664/4885PTGS2 803/4885MAPT 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.